Details werden geladen...
Press Release: Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes | The Manila Times
Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes
Ähnliche Seiten
Sanofi: Sanofi's Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes
https://www.finanznachrichten.de/nachrichten-2026-06/68757901-sanofi-sanofi-s-tzield-approved-in-the-us-as-the-first-disease-modifying-therapy-for-patients-recently-diagnosed-with-stage-3-type-1-diabetes-399.htm
Press Release: Sanofi’s Sarclisa subcutaneous approved in the EU as the first anticancer treatment administered via an on-body injector | The Manila Times
https://www.manilatimes.net/2026/06/08/tmt-newswire/globenewswire/press-release-sanofis-sarclisa-subcutaneous-approved-in-the-eu-as-the-first-anticancer-treatment-administered-via-an-on-body-injector/2360392Ambros Therapeutics Announces First Patient Dosed in Pivotal CRPS-RISE Phase 3 Clinical Trial of Neridronate in Patients with Complex Regional Pain Syndrome Type 1 | The Manila Times
https://www.manilatimes.net/2026/06/08/tmt-newswire/globenewswire/ambros-therapeutics-announces-first-patient-dosed-in-pivotal-crps-rise-phase-3-clinical-trial-of-neridronate-in-patients-with-complex-regional-pain-syndrome-type-1/2360811NewCelX Ltd. Submits Pre-IND Package to the FDA for NCEL-101 for the Treatment of Type 1 Diabetes | The Manila Times
https://www.manilatimes.net/2026/05/27/tmt-newswire/globenewswire/newcelx-ltd-submits-pre-ind-package-to-the-fda-for-ncel-101-for-the-treatment-of-type-1-diabetes/2352552Bayer Wins FDA Priority Review For Kerendia In Chronic Kidney Disease With Type 1 Diabetes
https://www.finanznachrichten.de/nachrichten-2026-05/68557764-bayer-wins-fda-priority-review-for-kerendia-in-chronic-kidney-disease-with-type-1-diabetes-020.htm